MDMA has been actively lobbying Capitol Hill to make the
necessary changes to recent patent reform legislation to ensure that medical
technology innovation flourishes. MDMA was successful in ensuring that harmful
proposals, such as the apportionment of damages in infringement cases and an
open-ended post-grant review system, were excluded from the America Invents Act
(ACA). MDMA continues to work with key members of Congress to reform the
current bill to strengthen the patent system, not weaken it.
The MDMA Patent Working Group meets on an "as needed" basis via teleconference. Email notification will be sent to all working group participants when a call has been scheduled. If you would like to join this working group, click here.
Joint Statement from MDMA, AAU, APLU, BIO, IA NSBA, NVCA, PhRMA, SBTC and USIJ on H.R. 9
Washington, D.C. - Joint Statement on H.R. 9...
MDMA Opposes House Patent Legislation That Would Thwart Innovation and Patient Care
Washington, D.C. - Mark Leahey, President & CEO of MDMA issued the following statement today opposing H.R.9, the "Innovation Act,"...
MDMA Statement on Senate Hearing on the "PATENT Act"
Washington, D.C. - Mark Leahey, President & CEO of MDMA issued the following statement today regarding the Senate Judiciary Committee hearing...
MDMA Letter Lays Out Concerns to House Judiciary Leadership on Patent Reform
Washington, D.C. – The Medical Device Manufacturers Association (MDMA) sent a letter to the Chairman and Ranking Member of...
House Judiciary Committee to Convene Hearing on H.R. 9 - The Innovation Act
On April 14 at 2pm ET before the full House Judiciary Committee, Chairman bob Goodlatte (VA) will...
MDMA Statement on House Legislation to Change the U.S. Patent System
Mark Leahey, President & CEO of MDMA, issued the following statement today regarding legislation...
MDMA Sends Letter to House Leadership on Patent Legislation
MDMA sent a letter to House Leadership this week expressing thoughts on the Innovation Act of 2013.
MDMA Sends Patent Stakeholder Letter to Congressional Leadership
MDMA and a
coalition of stakeholders sent a letter to House and Senate leadership
expressing concern over reports that application fees paid to the United States
Patent and Trademark Office (USPTO) are being diverted . . .
USPTO Issues Final Guidance for First-to-File Rule
Patent & Trade Office (USPTO) recently published final rules and guidance
implementing the first-inventor-to-file provision of the "America Invents
Act." The provision takes effect .
Webinar - First Inventor to File and Post-Grant Procedures Under the AIA